Ascletis Pharma Inc.
1672.HK·HKSE·Healthcare
5.515−0.440 (−7.39%)today
At close: Oct 22, 4:08 PM HKT · May be delayed up to 15 min · HKD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close5.955
Open5.830
Day range5.4205.865
52-week range5.40019.860
Off day high−5.97%
Off 52-week high−72.23%
Volume2.05M
Avg. volume (3M)2.42M
Market cap5.79B
EPS (TTM)-0.6100
Forward P/E-19.70
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.43
Shares outstanding1.05B
Short interest—
Earnings dateMar 26, 2025
Analyst target22.562
Profit margin0.00%
Against its peers
Compare in full ›| 1672.HK | ASND | ARWR | 688382.SS | AVIR | VIR | |
|---|---|---|---|---|---|---|
| Market cap | 5.79B | 15.99B | 8.24B | 8.33B | 324.83M | 1.76B |
| P/E (TTM) | — | 18.6 | — | — | — | — |
| Forward P/E | -19.7 | 22.5 | -11.7 | -43.6 | -2.7 | -4.2 |
| Price/book | 2.1 | 9.9 | 17.7 | 5.9 | 1.6 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −34.99% | +18.85% | +57.54% | −41.09% | +27.90% | +82.87% |
| Today | −7.39% | +1.71% | −0.82% | −7.05% | −0.74% | −1.32% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1672.HK news ›Hepatitis B Virus (HBV) Infection Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, GSK
Albany New York October 20 2026 As per DelveInsight s assessment globally Hepatitis B Virus HBV Infection pipeline constitutes 80 key companies continuously working towards developing 90 Hepatitis B Virus HBV Infection treatment therapies…
From articles in the 4Search news index.